Gilder Gagnon Howe & Co. LLC Sells 127 Shares of Insulet Co. (NASDAQ:PODD)

Gilder Gagnon Howe & Co. LLC cut its holdings in shares of Insulet Co. (NASDAQ:PODD) by 1.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,955 shares of the medical instruments supplier’s stock after selling 127 shares during the quarter. Gilder Gagnon Howe & Co. LLC’s holdings in Insulet were worth $2,599,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Integrated Wealth Concepts LLC grew its stake in Insulet by 39.1% in the fourth quarter. Integrated Wealth Concepts LLC now owns 3,562 shares of the medical instruments supplier’s stock valued at $930,000 after purchasing an additional 1,001 shares in the last quarter. Syon Capital LLC boosted its holdings in shares of Insulet by 5.6% in the 4th quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier’s stock valued at $291,000 after buying an additional 59 shares during the last quarter. Coppell Advisory Solutions LLC grew its stake in shares of Insulet by 135.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier’s stock valued at $74,000 after buying an additional 162 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Insulet by 0.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 202,728 shares of the medical instruments supplier’s stock worth $52,927,000 after buying an additional 744 shares during the last quarter. Finally, Dark Forest Capital Management LP raised its position in Insulet by 86.5% during the fourth quarter. Dark Forest Capital Management LP now owns 2,784 shares of the medical instruments supplier’s stock worth $727,000 after acquiring an additional 1,291 shares in the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the subject of a number of analyst reports. Citigroup lifted their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Raymond James reissued an “outperform” rating and set a $328.00 price target (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Royal Bank of Canada began coverage on Insulet in a research report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective for the company. Piper Sandler boosted their target price on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Wells Fargo & Company raised their price target on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $292.06.

Insider Buying and Selling

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares in the company, valued at approximately $888,525. This trade represents a 36.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.47% of the stock is owned by company insiders.

Insulet Stock Up 0.5 %

Shares of PODD opened at $260.71 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The firm’s 50 day moving average is $260.21 and its 200-day moving average is $261.69. The stock has a market capitalization of $18.31 billion, a PE ratio of 45.03, a P/E/G ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Equities research analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.